---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-057146"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T02:38:39.630898+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Atara expands tab-cel partnership worth up to $640M, cuts workforce 30%, Q3 loss $69.8M

## Summary
- Expanded global tab-cel deal with Pierre Fabre: up to $640M in payments, ~$30M upfront and $100M regulatory milestones, plus tiered double-digit royalties.
- Workforce reduction of ~30% to extend cash runway into Q3 2025; $7M in severance charges expected.
- Q3 net loss $69.8M ($0.66/sh) vs $84.1M ($0.82/sh) in prior year; cash, equivalents, and investments $102.4M at Sep 30.
- ATA188 Phase 2 EMBOLD primary analysis on track for early Nov; focus shifts to ATA188 and AlloCAR-T programs.

## SEC filing metadata
- accession: 0000950170-23-057146
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017023057146/0000950170-23-057146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017023057146/atra-20231031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-057146
- JSON: https://secwatch.observer/filing/0000950170-23-057146.json
- Plain text: https://secwatch.observer/filing/0000950170-23-057146.txt

## Key facts
- Earnings Releases
  Atara Biotherapeutics, Inc. reported third quarter ended September 30, 2023 results: net income net loss of $69.8 million, EPS $0.66 per share.
  - Period: third quarter ended September 30, 2023
  - Net income: net loss of $69.8 million
  - EPS: $0.66 per share
  - Result: reported results
  source text: Atara reported a net loss of $69.8 million, or $0.66 per share for the third quarter 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017023057146/0000950170-23-057146-index.htm
- Material Agreements
  Atara Biotherapeutics, Inc. amended Amended and Restated Commercialization Agreement with Pierre Fabre Medicament valued at $20 million (effective 2023-10-31).
  - Action: amendment
  - Agreement: license
  - Counterparty: Pierre Fabre Medicament
  - Value: $20 million
  - Effective: 2023-10-31
  source text: On October 31, 2023, Atara Biotherapeutics, Inc. (the “Company”) entered into an Amended and Restated Commercialization Agreement (the “A&R Commercialization Agreement”) with Pierre Fabre Medicament (“Pierre Fabre”), which amends and restates that certain Commercialization Agreement dated October 2, 2021, as amended on September 27, 2022 (the “Original Commercialization Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017023057146/0000950170-23-057146-index.htm
- Restructurings & Charges
  Atara Biotherapeutics, Inc. announced a restructuring with charges of approximately $7.0 million in total for severance and related benefits (approximately 30% of its current employees).
  - Type: restructuring
  - Charge: approximately $7.0 million in total for severance and related benefits
  - Headcount: approximately 30% of its current employees
  source text: On November 1, 2023, the Company announced a reduction in its workforce that will impact approximately 30% of its current employees. The Company expects to substantially complete the workforce reduction by December 31, 2023. The Company expects to recognize approximately $7.0 million in total for severance and related benefits for employees laid off under the reduction in force.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017023057146/0000950170-23-057146-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.